Amr Ellabban
speaker
114 appearances
2 recordings
1 series
first heard Nov 2021
last heard Feb 2023
Amr Ellabban’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
And hopefully we'll be able to retrain everyone to adapt to that.
That's a topic for another day.
I think we're we're all out of time.
So thank you very much, John, for joining us.
And for folks who want to get get in touch and discuss this more, how can they reach you?
Fantastic.
Well, thank you so much, John, for joining us today and thank you everyone for listening.
Welcome to Orbit, the HG podcast series where we speak to leaders and innovators from across the software and tech ecosystem to discuss the key trends that change how we all do business.
I'm Amr Laban, head of data and analytics here in the HG Portfolio team, and with me today is John Moser, SVP of Innovation Research and Development at Evaluate, an HG portfolio company focused on the pharmaceutical space.
Thanks for joining me, John.
Happy to be here, Emma.
To start with, why don't you tell us a bit more about yourself, John?
Sounds like a super cool role to be in.
And maybe the place we should have started is why don't you tell us a bit about Evaluate and what it is you do as a business?
I guess no surprise, I'm really excited to dive into some of the data and insights.
But before we go there, uh just thinking biopharma has been under a lot of scrutiny over the past few years, especially with the advent of COVID.
What are the major challenges facing the industry right now?
Those are some pretty crazy numbers.
What comes next?
Speaking of pricing, farmers had a bad reputation recently around kind of the price of drugs.
Showing 61–80 of 114 · page 4 of 6
← Previous
Next →